Dendrimer-based BH3 conjugate that targets human carcinoma cells
Related Experiment Video
Updated: Jul 11, 2026
Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo
Published on: February 5, 2021
Andrzej Myc1, Anil K Patri, James R Baker
1Michigan Nanotechnology Institute for Medicine and Biological Sciences, University of Michigan Medical School, BSRB, Ann Arbor, MI 48109-0648, USA. myca@umich.edu
Abstract:
Our previous studies have demonstrated the efficacy of generation 5 poly(amidoamine) dendrimers (G5-PAMAM) as a platform for the targeted delivery of chemotherapeutics. However, anticancer therapy can be subverted by anti-apoptotic changes in cancer cells. Bcl-2 and several of its peptides are commonly overexpressed in a number of cancers. A means to reverse this anti-apoptotic mechanism is to expose the cells to BH3 peptide, which has a homology to the anti-apoptotic Bcl-2 protein. This cannot be done indiscriminately because it can induce apoptosis in normal cells. In order to specifically target BH3 peptides to cancer cells, we synthesized a trifunctional, G5-PAMAM-based nanodevice to which folic acid was conjugated as a targeting agent, along with fluorescein isothiocyanate as the reporter agent and BH3 peptides that were used to induce apoptosis. The results show, for the first time, the therapeutic potential of targeted BH3 peptides as a means of inducing apoptosis by interfering with anti-apoptotic proteins within specific cells.
Insights
This study developed a targeted nanodevice using generation 5 poly(amidoamine) dendrimers (G5-PAMAM) to deliver BH3 peptides specifically to cancer cells, overcoming anti-apoptotic resistance and inducing cancer cell death.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Cancer Biology
Background:
- Anticancer therapy faces challenges from cancer cell anti-apoptotic mechanisms, often involving Bcl-2 overexpression.
- BH3 peptides can reverse this anti-apoptotic effect but require targeted delivery to avoid harming normal cells.
Purpose of the Study:
- To develop a targeted nanodevice for delivering BH3 peptides specifically to cancer cells.
- To investigate the therapeutic potential of targeted BH3 peptides in inducing cancer cell apoptosis.
Main Methods:
- Synthesized a trifunctional G5-PAMAM nanodevice.
- Conjugated folic acid as a targeting agent and BH3 peptides for apoptosis induction.
- Utilized fluorescein isothiocyanate as a reporter agent.
Main Results:
- Demonstrated the successful synthesis of the targeted G5-PAMAM nanodevice.
- Showcased the potential of BH3 peptides to induce apoptosis by interfering with anti-apoptotic proteins.
- Confirmed targeted delivery of BH3 peptides to cancer cells.
Conclusions:
- The G5-PAMAM-based nanodevice effectively targets cancer cells for BH3 peptide delivery.
- Targeted BH3 peptides show significant therapeutic potential for overcoming cancer's anti-apoptotic defenses.
- This approach offers a novel strategy for cancer treatment by selectively inducing apoptosis.
